Insider Buying: IQVIA Holdings Inc. (NYSE:IQV) Director Acquires $255,739.50 in Stock

IQVIA Holdings Inc. (NYSE:IQV) Director John G. Danhakl purchased 1,275 shares of the company’s stock in a transaction on Tuesday, December 3rd. The stock was acquired at an average cost of $200.58 per share, for a total transaction of $255,739.50. Following the completion of the purchase, the director now owns 1,275 shares of the company’s stock, valued at approximately $255,739.50. This trade represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

IQVIA Price Performance

Shares of IQVIA stock opened at $208.13 on Monday. The stock has a market capitalization of $37.78 billion, a price-to-earnings ratio of 27.75, a price-to-earnings-growth ratio of 2.25 and a beta of 1.48. The company has a fifty day moving average of $200.67 and a 200-day moving average of $219.40. IQVIA Holdings Inc. has a 52-week low of $187.62 and a 52-week high of $261.73. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.81 and a current ratio of 0.84.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Equities research analysts expect that IQVIA Holdings Inc. will post 10.81 EPS for the current year.

Analysts Set New Price Targets

Several research firms recently weighed in on IQV. Truist Financial cut their price target on shares of IQVIA from $265.00 to $261.00 and set a “buy” rating on the stock in a report on Thursday, December 12th. UBS Group cut their target price on IQVIA from $260.00 to $255.00 and set a “buy” rating on the stock in a research note on Friday. Royal Bank of Canada restated an “outperform” rating and issued a $270.00 price objective on shares of IQVIA in a research note on Wednesday, December 11th. JPMorgan Chase & Co. cut their price target on shares of IQVIA from $279.00 to $240.00 and set an “overweight” rating on the stock in a report on Tuesday, November 5th. Finally, BTIG Research downgraded shares of IQVIA from a “buy” rating to a “neutral” rating in a report on Monday, February 3rd. Five analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $252.39.

Hedge Funds Weigh In On IQVIA

A number of hedge funds and other institutional investors have recently made changes to their positions in IQV. Smith Group Asset Management LLC bought a new position in IQVIA in the 4th quarter worth $1,616,000. Simplify Asset Management Inc. raised its stake in IQVIA by 67.8% in the third quarter. Simplify Asset Management Inc. now owns 9,637 shares of the medical research company’s stock worth $2,284,000 after buying an additional 3,894 shares in the last quarter. Nordea Investment Management AB lifted its holdings in IQVIA by 47.4% in the fourth quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock worth $277,908,000 after buying an additional 452,029 shares during the period. Fifth Third Bancorp boosted its position in IQVIA by 13.0% during the 4th quarter. Fifth Third Bancorp now owns 13,179 shares of the medical research company’s stock valued at $2,590,000 after acquiring an additional 1,521 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its holdings in shares of IQVIA by 46.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock worth $437,378,000 after acquiring an additional 583,396 shares during the period. Institutional investors own 89.62% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.